| Revenue growth | Q2 +40.1%; H1 +38.6% YoY |
|---|---|
| Margins | EBITDA margin 14.4% Q2 vs 11.1% Q2 FY26 |
| Demand visibility | Customers in 80+ countries; no order book disclosed |
Growth
Q2 revenue +40.1%, EBITDA +79.6%, PAT +116.8% YoY. Pharma H1 ₹942 Cr (+41.5%).
Outlook
₹495 Cr plan: ₹350 Cr ibuprofen expansion (FY28), ₹110 Cr CDMO and ₹35 Cr tolling (FY27), funded by internal accruals.
Risks
Weak cash conversion: H1 operating cash flow ₹8.3 Cr. Receivables rose to ₹689 Cr, inventories to ₹464 Cr.
Last quarter's promises, checked
Delivered
- Guided ~15–20% growth (FY27 financial guidance) → H1 revenue +38.6% (= BEAT)
- Guided margins 'more or less same', with probable expansion → EBITDA margin 14.4% vs 11.1% (= BEAT)
Partly delivered
- Guided CDMO commercialisation by Q3 FY27 → no commercial start confirmed in deck (= PARTIAL)
- Guided Ibuprofen 6,000 MTPA commissioning by Dec 2027 → no progress disclosed (= PARTIAL)
Missed
- Guided internal-accrual funding backed by cash generation → H1 operating cash flow ₹8.3 Cr; current borrowings ₹194 Cr vs ₹132 Cr (= MISS)
Investor Presentation filed with NSE, NSE: IOLCP. Summary written with AI assistance from the document.
IOL Chemicals and Pharmaceuticals Ltd: key numbers
- Share price
- ₹177.65
- Market cap
- ₹5,215 Cr
- Revenue (annual)
- ₹2,319 Cr
- Net profit (annual)
- ₹137.6 Cr
- P/E (TTM)
- 31.0×Sector 45.9×
- Promoter holding
- 62.28%+0.00% QoQ
- FII holding
- 7.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from IOL Chemicals and Pharmaceuticals Ltd
All →IOL Chemicals and Pharmaceuticals Results Update
IOL Chemicals reported record quarterly revenue, EBITDA and profit for Q2 FY27 and half-year results. Standalone growth was strong, with margins expanding year-on-year.
IOL Chemicals and Pharmaceuticals Q2 FY27 Results: Net Profit ₹65.1 Cr, Up 117.0% YoY
IOL Chemicals and Pharmaceuticals Ltd reported revenue from operations of ₹795 Cr (+40.1% YoY) and net profit of ₹65.1 Cr (+117.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹65.1 Cr · +117.0% YoY
IOL Chemicals and Pharmaceuticals Board Meeting Date
IOL Chemicals scheduled its board meeting for 30 Oct 2026 to consider unaudited Q1/H1 results. Trading window remains closed until 2 Nov 2026.
IOL Chemicals and Pharmaceuticals Other Announcement
The company submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.
IOL Chemicals and Pharmaceuticals Regulatory Approval
IOL Chemicals and Pharmaceuticals Limited received EU-REACH registration for its product 'Triacetin', enabling the company to export this product to countries in the European Union.
IOL Chemicals and Pharmaceuticals Other Announcement
IOL Chemicals and Pharmaceuticals Limited informed the Exchange about the dispatch of reminder letters to shareholders holding physical shares for updating their KYC details.